Table 3.
Metallic Nanoparticles applied to the treatment of systemic infections.
| Formulation name | Active Principle | Composition | Therapeutic target | Route of administration | Reference |
|---|---|---|---|---|---|
| CeO2 NPs | CeO2 | CeO2 | Polymicrobial sepsis | Intravenous | Selvaraj et al., 2015 |
| CM-SH-AuNPs | Au | Au, cecropin, melittin and cysteine | Polymicrobial sepsis | Intraperitoneal | Rai et al., 2016 |
| AuNPs | Au | Au | Polymicrobial sepsis | Intravenous | Taratummarat et al., 2018 |
| CeO2 CSNPs | CeO2 | CeO2 | lipopolysaccharide (LPS) induced sepsis | Intravenous | Chen and Xu, 2018 |
| AgNPs | Ag | Ag | Sepsis by P. aeruginosa | Topical | El Din et al., 2016 |
| AUNC-L-Amp | Au | Au | Systemic MRSA | Intraperitoneal | Kalita et al., 2018 |
| SPIONs | γ-Fe2O3 | γ-Fe2O3 | Lipopolysaccharide (LPS) induced sepsis | Intravenous | Xu et al., 2019a, Xu et al., 2019b |
CeO2 NPs: cerium oxide nanoparticles; CeO2: cerium oxide; AuNPs: gold nanoparticles; Au: gold; CeO2 CSNPs: cerium oxide nanoparticles from Camellia sinens; CM-SH: cecropin melittin with cysteine; LPS: lipopolysaccharide; AgNPs: silver nanoparticles; Ag: silver; AUNC-L-Amp: lysozyme capped gold nanoclusters with β-lactam antibiotic ampicillin MRSA: Methicillin Resistant Staphylococcus aureus.